Orthocell Ltd (ASX:OCC, OTC:ORHHF) has recorded its first 100 unit sales of peripheral nerve repair product Remplir™ in the US, marking an early adoption milestone as the company builds out its commercial footprint in a market it estimates at US$1.6 billion.
Overall, OCC is targeting a total addressable market across selected jurisdictions of more than US$3.5 billion
Plurilock Security Inc (TSX-V:PLUR, OTCQB:PLCKF), a global cybersecurity systems integrator, said on Wednesday it has signed a two-year software licensing agreement valued at C$2.45 million with a Nasdaq-listed semiconductor manufacturer.
The customer, which has worked with Plurilock since 2024, will use the company’s advanced insider-risk software solution, delivered through one of Plurilock’s strategic technology partners.
NanoViricides (NYSE-A:NNVC) is gearing up to tackle multiple viral threats with Phase 2 trials for its broad-spectrum antiviral NV-378, as analysts at Alliance Global Partners kick off coverage with a Buy rating and $6 price target.
The biotechnology company, which is developing innovative antiviral therapies, is advancing its lead candidate NV-378 into Phase 2 trials next year, targeting a range of viral infections including Mpox, influenza, COVID-19, and respiratory syncytial virus (RSV), according to analysts at Alliance Global Partners.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Wednesday it has dosed the first patient in a Phase 2 clinical trial testing its intranasal drug candidate foralumab in patients with early Alzheimer’s disease.
The randomized, placebo-controlled study will evaluate foralumab as a standalone treatment and in combination with FDA-approved anti-amyloid drugs lecanemab (Leqembi) or donanemab in people with early or mild Alzheimer’s, the company said.
1911 Gold Corp (TSX-V:AUMB, OTCQB:AUMBF) said it has begun a 2,200-metre diamond drilling program at its Ogama-Rockland gold deposit in Manitoba, as it looks to expand and confirm resources near its True North gold project.
The program comprises eight surface drill holes targeting down-dip and along-strike extensions of high-grade, shallow gold mineralization hosted in quartz veins.
Protalix Biotherapeutics Inc (NYSE-A:PLX) announced that it has entered into a collaboration and option agreement with Secarna Pharmaceuticals to jointly develop new antisense oligonucleotide (ASO) therapies targeting rare kidney diseases, the companies said Tuesday.
Secarna, headquartered in Martinsried, Germany, specializes in the discovery and development of oligonucleotide-based therapeutics.
Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF) has announced that Patrick Cheetham will transition to non-executive chairman, with effect from 1 January.
Cheetham, the company's founder and chair, who has led it for over 26 years, is stepping back from his having an executive role. It follows the appointment of Dr Richard Belcher as managing director in March.
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) has launched a new technical paper series on non-fatigue driver impairment, beginning with the impact of alcohol.
The company said its research supports the use of in-vehicle Driver Monitoring System (DMS) technology to detect real-time functional impairment.